Anteris Technologies Global Corp. — Capital/Financing Update 2023

Feb 14, 2023

ASX ANNOUNCEMENT

15 February 2023

CLEANSING NOTICE UNDER SECTION 708A(5)(e)

On 15 February 2023, Anteris Technologies Ltd (ASX: AVR) ( Anteris or the Company ) announced that it issued 1,454,167 new fully paid Ordinary Shares ( New Shares ) to various sophisticated and professional investors at an issue price of $24.00 per new share, raising $35 million before issue costs.

Details of the securities issued

Class of securities: Fully paid ordinary shares ASX code: AVR Date of the issue: 15 February 2023 Total number of securities issued: 1,454,167

Anteris gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Corporations Act ) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;

2. as at the date of this notice, the Company has complied with:

   • (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (b) section 674 of the Corporations Act;

3. as at the date of this notice, there is no ‘excluded information’ of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

Anteris Technologies Ltd Registered Office:

T +61 1300 550 310 | F +61 1300 972 437 | E info.au@anteristech.com | W anteristech.com

==> picture [95 x 51] intentionally omitted <==

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066 Customer Service

Brisbane ▪ Minneapolis ▪ Geneva ▪ Malaga

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris’ DurAVR[TM] 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.

The proven benefits of its patented ADAPT[®] tissue technology, paired with the unique design of our DurAVR[TM] 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Investor contact

Deanne Curry GRACosway E: investors@anteristech.com M: +61 414 388 997

Media contact

Nick Howe GRACosway nhowe@gracosway.com.au M: +61 407 183 221

www.anteristech.com Twitter: @AnterisTech Facebook: www.facebook.com/AnterisTech

LinkedIn: https://www.linkedin.com/company/anteristech

==> picture [95 x 52] intentionally omitted <==